An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?

1996 ◽  
Vol 32 (11) ◽  
pp. 1949-1956 ◽  
Author(s):  
J.W. Chapman ◽  
D. Murray ◽  
D.R. McCready ◽  
W. Hanna ◽  
H.J. Kahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Statistical Approach

scholarly journals The role of genetic breast cancer susceptibility variants as prognostic factors

2012 ◽  
Vol 21 (17) ◽  
pp. 3926-3939 ◽  
Author(s):  
Peter A. Fasching ◽  
Paul D.P. Pharoah ◽  
Angela Cox ◽  
Heli Nevanlinna ◽  
Stig E. Bojesen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Susceptibility ◽  
Breast Cancer Susceptibility

The role of core biopsy in the preoperative classification of breast cancer according to prognostic factors

2013 ◽  
Vol 85 (1) ◽  
pp. 1-7
Author(s):  
S. Lanitis ◽  
P. Lazari ◽  
Ch. Kontovounisios ◽  
Ch. Karaliotas ◽  
G. Sgourakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Core Biopsy

Prognostic role of triple-negative subtype in breast cancer patients with brain metastases.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 36-36 ◽  
Author(s):  
A. Mathew ◽  
M. Q. Rosenzweig ◽  
A. Brufsky
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cohort Study ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Triple Negative ◽  
Hazard Ratio ◽  
Her2 Positive ◽  
Risk Of Death

36 Background: Metastatic breast cancer (MBC) patients with brain metastases (BM) have a poorer prognosis compared to patients with metastases to sites such as bone or other visceral organs. The role of breast cancer subtypes such as triple negative (TN) status and its relationship with other known prognostic factors have not been well delineated in the context of metastatic disease to the brain. We conducted a retrospective single institution cohort study of MBC patients with BM to evaluate the association between TN subtype and overall survival from the diagnosis of BM. Methods: Baseline demographic and tumor specific data including ER, PR and HER2 status were collected on newly diagnosed MBC patients between January 1998 and December 2009. Overall survival was determined from the date of diagnosis of BM. Survival analyses were performed using the Kaplan-Meier method and Cox proportional-hazards model. Results: Data were available on 186 MBC patients with BM, of whom 156 died during a median follow-up of 10.2 months from the diagnosis of BM; median age was 47.9 years. 91% of patients were Caucasian; 25.3% had triple negative disease. Median survival from the period of diagnosis of BM in patients with triple negative disease was 7 months (Interquartile range, IQR: 3–13) as compared to 11 months (IQR: 5–22) in patients who were HER2-positive or ER/PR-positive. Multivariate analysis found a higher risk of death after BM for TN disease subtype, with a hazard ratio for death of 2.89 (95% confidence interval: 1.89–4.44; p<0.001), when adjusted for variables such as age and stage at initial diagnosis of breast cancer, race, the number of metastatic sites, and the use of metastatic chemotherapy. The administration of metastatic chemotherapy had a significant survival benefit in the analyses, with a hazard ratio for death of 0.52 (95% CI: 0.27–0.99; p=0.048). Conclusions: This retrospective cohort study in MBC patients with BM provides evidence for a greater risk of death in those with TN disease as compared to HER2-positive or ER/PR-positive subtypes even after adjusting for other prognostic factors.

ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1572-1572
Author(s):  
Yuksel Urun ◽  
Tulay Koru-Sengul ◽  
Kadri Altundag ◽  
Gungor Utkan ◽  
Handan Onur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Blood Types ◽  
Abo Blood Type

1572 Background: The role of genetic factors in the development of cancer is widely accepted. ABO blood type is an inherited characteristic and previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. Methods: All patients who had breast cancer (BC) and treated between 2000-2010 at the Departments of Medical Oncology of both Ankara and Hacettepe Universities (Ankara, Turkey) with defined ABO blood type and Rh factor were included in our retrospective reviews of tumor registry records. A group of volunteer healthy women donors of Turkish Red Crescent between 2004-2011 were identified as a control group, without any matching factors. The relationship of ABO blood types and Rh factor with various prognostic factors such as age at diagnosis, menopausal status, family history of breast cancer, and ER/PR/HER2 status were evaluated from 1740 BC patients. We compared the distributions of ABO blood types, Rh factors among 1740 patients and 204,553 healthy controls. Among BC patients, differences between each of aforementioned ABO blood groups and Rh factors with respect to various prognostic factors were explored, respectively. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (44% A, 8% AB, 16% B, 32% O, 88% Rh+) and controls (41% A, 8% AB, 16% B, 35% O, 87% Rh+). However, there were statistically significant differences between patients and controls with respect to A vs. nonA (p=0.019) and marginal significance (p=0.051) for O vs. nonO. Among patients, there were statistically significant differences between A and nonA with respect to HER2 (p=0.0421), M stage (p=0.0447), T stage (p=0.0020). Only T stage (p=0.0337) were significantly different between O vs nonO. Grade (p=0.0227) and M stage (p=0.0107) were significantly different between Rh factors. Conclusions: In our study sample, ABO blood type was statistically significantly associated with breast cancer. Additional studies are necessary to determine the mechanisms by which ABO blood type may influence the risk of breast cancer.

Role of Blood Groups as Prognostic Factors in Primary Breast Cancer

Oncology ◽  
1990 ◽  
Vol 47 (4) ◽  
pp. 308-312 ◽  
Author(s):  
Massimo Costantini ◽  
Tiziana Fassio ◽  
Luciano Canobbio ◽  
Marco Landucci ◽  
Massimo Resasco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Primary Breast Cancer ◽  
Blood Groups

The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome

2004 ◽  
Vol 204 (1) ◽  
pp. 93-100 ◽  
Author(s):  
AR Panigrahi ◽  
SE Pinder ◽  
SY Chan ◽  
EC Paish ◽  
JFR Robertson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Signalling Pathways

The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old

2008 ◽  
Vol 26 (1) ◽  
pp. 45 ◽  
Author(s):  
Eun Seog Kim ◽  
Doo Ho Choi ◽  
So Young Jin ◽  
Dong Wha Lee ◽  
Hee Sook Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Tissue Microarray ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document